Item 2. Management’s Discussion and Analysis
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS.
Management’s Discussion and Analysis of
Financial Condition and Results of Operations (“MD&A”) in this Form 10-Q is provided as a supplement to, and should be
read in conjunction with, our audited consolidated financial statements, the accompanying notes, and the MD&A included in our Annual
Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”). Unless otherwise specified, any description
of “our”, “we”, and “us” in this MD&A refer to Lifeway Foods, Inc. (“Lifeway”) and
our wholly-owned subsidiaries.
Cautionary Statement Regarding Forward-Looking
Statements
In addition to historical information, this quarterly
report contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as “anticipate,” “from
time to time,” “intend,” “plan,” “ongoing,” “realize,” “should,” “may,”
“could," "believe," "future," "depend," "expect," "will," "result,"
"can," "remain," "assurance," "subject to," "require," "limit," "impose,"
"guarantee," "restrict," "continue," "become," "predict," "likely," "opportunities,"
"effect," "change," "predict," and "estimate,” and similar terms or terminology, or the negative
of such terms or other comparable terminology. Examples of forward-looking statements include, among others, statements we make regarding:
·
Expectations of the effect on our financial condition of claims, litigation, environmental costs, contingent liabilities and governmental and regulatory investigations and proceedings, if any;
·
Strategy for acquisitions, customer retention, growth, product development, market position, financial results and reserves;
·
Estimates of the amounts of sales allowances and discounts to our customers and consumers;
·
Our belief that we will maintain compliance with our loan agreements and have sufficient liquidity to fund our business operations.
Forward looking statements are based on management’s
beliefs, assumptions, estimates and observations of future events based on information available to our management at the time the statements
are made and include any statements that do not relate to any historical or current fact. These statements are not guarantees of future
performance and they involve certain risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may
differ materially from what is expressed, implied or forecast by our forward-looking statements due in part to the risks, uncertainties,
and assumptions that include:
·
Changes in the pricing of commodities;
·
The actions and decisions of our competitors and customers, including those related to price competition;
·
Our ability to successfully implement our business strategy;
·
The effects of government regulation;
·
Disruptions to our supply chain, or our manufacturing and distribution capabilities, including those due to cybersecurity threats; and
·
Such other factors as discussed throughout Part I, Item 1 “Business”; Part I, Item 1A “Risk Factors”; and Part II, Item 7 “Management's Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for the year ended December 31, 2023 , Part II, Item 1A of this Form 10-Q and that are described from time to time in our other periodic reports filed with the SEC.
These factors are not necessarily all of the important
factors that could cause actual results to differ materially from those expressed in any of our forward-looking statements. Other unknown
or unpredictable factors could also have material adverse effects on future results. The Company intends these forward-looking statements
to speak only at the date made. Except as otherwise required to be disclosed in periodic reports required to be filed by public companies
with the SEC pursuant to the SEC's rules, Lifeway has no duty to update these statements, and it undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
20
Business Overview
Lifeway was founded in 1986 by Michael Smolyansky,
ten years after he and his family emigrated from Eastern Europe to the United States. Lifeway was the first to successfully introduce
kefir to the U.S. consumer on a commercial scale, initially catering to ethnic consumers in the Chicago, Illinois metropolitan area. Lifeway
has grown to become the largest producer and marketer of kefir in the U.S. and an important player in the broader market spaces of probiotic-based
products and natural, “better for you” foods.
Our primary product is drinkable kefir, a cultured
dairy product. Lifeway Kefir is tart and tangy, high in protein, calcium and vitamin D. The Company manufactures (directly or through
a co-manufacturer) and markets products under the Lifeway, Fresh Made, and GlenOaks Farms brand names, as well as under private labels
on behalf of certain customers.
The Company’s product categories are:
·
Drinkable Kefir, a cultured dairy product sold in a variety of organic and non-organic sizes, flavors, and types.
·
European-style soft cheeses, including farmer cheese, white cheese, and Sweet Kiss.
·
Cream and other, which primarily consists of cream, a byproduct of raw milk processing.
·
Drinkable Yogurt, sold in a variety of sizes and flavors.
·
ProBugs, a line of kefir products designed for children.
·
Other Dairy, which primarily consists of Fresh Made butter and sour cream.
Products
In October 2024, we began to roll out our first
products with 100% lactose free labeling. Our products were already up to 99% lactose free, so we are pleased to further attract consumers
with our new Organic Whole Milk Flavor Fusion items that have this added benefit, along with decreased sugar content. New on-trend flavors
like Hot Honey, Matcha Latte, and Passionfruit Lychee – just to name a few – are amazing additions to our portfolio. The entire
lineup is loaded with high-quality bioavailable nutrients, and plays to our strengths, as our organic products have been incredibly successful
to date.
We expect health and wellness trends to continue
to be a tailwind for our entire premium product portfolio. We plan to continue to invest behind our key products to capture more and more
of this growing market,
Distribution Strategy
In September 2024, we announced our first expansion
of Kefir distribution in the South African market. In November 2024, we announced our expansion within Dubai and the UAE. The offering
of 32oz Lifeway Kefir, 8oz Lactose-Free Lifeway Kefir, ProBugs and farmer cheese, exported from the United States, is expected to begin
shipping in the fourth quarter of 2024 and will become available in supermarkets and hypermarkets in Dubai and across the Emirates. We
are taking a measured, and thoughtful approach to global expansion, as we seek markets that are primed for success and can be accessed
without a major initial investment.
Unsolicited Offer
On November 5, 2024, we announced that our board
of directors (our “Board”) determined after careful and thorough consideration, in consultation with its independent financial
and legal advisors, that the unsolicited proposal made on September 23, 2024 by Danone North America PBC (“Danone”) to acquire
all of the shares of the Company that it does not already own for $25.00 per share substantially undervalues the Company and is not in
the best interests of the Company and its stockholders or other stakeholders. In connection with that determination, we entered into a
Shareholder Rights Agreement with Computershare Trust Company, N.A., as rights agent (the “Rights Agreement”). Pursuant to
the Rights Agreement, our Board declared a dividend of one preferred share purchase right (each a “Right”) for each outstanding
share of Company common stock to stockholders of record as of the close of business on November 18, 2024. Each Right entitles its holder,
subject to the terms of the Rights Agreement, to purchase from the Company one one-thousandth of one share of Series A Junior Participating
Preferred Stock, no par value, of the Company at an exercise price of $130.00 per Right, subject to adjustment. Rights will attach to
any shares of Company common stock that become outstanding after November 18, 2024 and prior to the earlier of the Distribution Time (as
defined in the Rights Agreement) and the redemption or expiration of the Rights, and in certain other circumstances described in the Rights
Agreement.
21
Trends and Uncertainties
Current Macroeconomic Environment
We have not experienced significant supply chain
disruptions or labor supply shortages and have continued to satisfy customer and consumer demand for our products. Management continues
to proactively manage the supply and transportation of materials used to produce and package our products, staffing, and transportation
of our products to customers. This proactive planning has allowed the Company to meet increased demand.
Results of Operations
Three Months Ended September 30, 2024 Compared to Three Months
Ended September 30, 2023
The following table presents certain information
concerning our financial results, including information presented as a percentage of consolidated net sales:
Three Months Ended September 30,
2024
2023
$
%
$
%
Net sales
46,095
100.0%
40,896
100.0%
Cost of goods sold
33,508
72.7%
29,099
71.2%
Depreciation expense
720
1.6%
654
1.6%
Total cost of goods sold
34,228
74.3%
29,753
72.8%
Gross profit
11,867
25.7%
11,143
27.2%
Selling expense
3,979
8.6%
2,884
7.1%
General & administrative expense
3,564
7.7%
3,085
7.5%
Amortization expense
135
0.3%
135
0.3%
Total operating expenses
7,678
16.6%
6,104
14.9%
Income from operations
4,189
9.1%
5,039
12.3%
Other income (expense):
Interest expense
(4
)
(0.0%
)
(109
)
(0.3%
)
Gain on sale of property and equipment
3
0.0%
–
0.0%
Other income (expense), net
138
0.3%
(1
)
0.0%
Total other income (expense)
137
0.3%
(110
)
(0.3%
)
Income before provision for income taxes
4,326
9.4%
4,929
12.0%
Provision for income taxes
1,350
2.9%
1,517
3.7%
Net income
2,976
6.5%
3,412
8.3%
Net Sales
Net sales were $46,095 for the three-month period
ended September 30, 2024, an increase of $5,199 or 12.7% versus prior year. The net sales increase was primarily driven by higher volumes
of our branded drinkable kefir.
Gross Profit
Gross profit as a percentage of net sales was
25.7% and 27.2% in the three-month period ended September 30, 2024 and 2023, respectively. The decrease versus the prior year was primarily
due to unfavorable milk pricing, partially offset by favorable transportation costs.
22
Selling Expense
Selling expenses increased by $1,095 to $3,979
during the three-month period ended September 30, 2024 from $2,884 during the same period in 2023. Selling expenses as a percentage of
net sales increased to 8.6% in the three-month period ended September 30, 2024 from 7.1% during the same period in 2023. The increase
is primarily driven by our continued investments in marketing activities.
General and Administrative Expense
General and administrative expenses increased
$479 to $3,564 during the three-month period ended September 30, 2024 from $3,085 during the same period in 2023. General and administrative
expenses as a percentage of net sales increased to 7.7% in the three-month period ended September 30, 2024 from 7.5% during the same period
in 2023.
Provision for Income Taxes
The provision for income taxes was $1,350 and
$1,517 during the three months ended September 30, 2024 and 2023, respectively.
The effective income tax rate for the three months
ended September 30, 2024 was 31.2% compared to 30.8% in the same period last year. The statutory Federal and state tax rates remained
consistent from 2024 to 2023. The Company has items that are nondeductible or are discrete adjustments to tax expense. The Company consistently
reflects non-deductible officer compensation expense, non-deductible compensation expense related to equity incentive awards and separate
state tax rates from period to period. Although similar items were reflected in 2023, the percentage effect is different due to the difference
in pre-tax income in 2024 compared to 2023.
The Company’s effective tax rate may change
from period to period based on recurring and non-recurring factors including the relative mix of pre-tax earnings (or losses), the jurisdictional
mix of earnings, enacted tax legislation, state income taxes, the impact of non-deductible items, changes in valuation allowances, settlement
of tax audits, and the expiration of the statute of limitations in relation to unrecognized tax benefits. The Company records discrete
income tax items such as enacted tax rate changes and completed tax audits in the period in which they occur.
Income taxes are discussed in Note 10 in the Notes
to the Consolidated Financial Statements.
Nine months Ended September 30, 2024 Compared to Three Months
Ended September 30, 2023
The following table presents certain information
concerning our financial results, including information presented as a percentage of consolidated net sales:
Nine months Ended September 30,
2024
2023
$
%
$
%
Net sales
139,886
100.0%
118,030
100.0%
Cost of goods sold
101,127
72.3%
85,428
72.4%
Depreciation expense
2,082
1.5%
1,953
1.7%
Total cost of goods sold
103,209
73.8%
87,381
74.1%
Gross profit
36,677
26.2%
30,649
25.9%
Selling expense
11,256
8.0%
8,974
7.6%
General & administrative expense
11,877
8.5%
10,028
8.5%
Amortization expense
405
0.3%
405
0.3%
Total operating expenses
23,538
16.8%
19,407
16.4%
Income from operations
13,139
9.4%
11,242
9.5%
Other income (expense):
Interest expense
(102
)
(0.1%
)
(322
)
(0.3%
)
Gain on sale of property and equipment
3
0.0%
33
0.0%
Other income (expense), net
153
0.1%
(1
)
0.0%
Total other income (expense)
54
0.0%
(290
)
(0.3%
)
Income before provision for income taxes
13,193
9.4%
10,952
9.2%
Provision for income taxes
4,008
2.9%
3,554
3.0%
Net income
9,185
6.5%
7,398
6.2%
24
Net Sales
Net sales were at $139,886 for the nine-month
period ended September 30, 2024, an increase of $21,856 or 18.5% versus prior year. The net sales increase was primarily driven by higher
volumes of our branded drinkable kefir.
Gross Profit
Gross profit as a percentage of net sales was
26.2% and 25.9% during the nine-month period ended September 30, 2024 and 2023, respectively. The increase versus the prior year was primarily
due to the higher volumes of our branded products, which provided manufacturing efficiencies and favorable fixed cost absorption.
Selling Expense
Selling expense increased by $2,282 to $11,256
during the nine-month period ended September 30, 2024 from $8,974 during the same period in 2023. Selling expenses as a percentage of net
sales increased to 8.0% in the three-month period ended September 30, 2024 from 7.6% during the same period in 2023.
General and Administrative Expense
General and administrative expense increased $1,849
to $11,877 during the nine-month period ended September 30, 2024 from $10,028 during the same period in 2023. The increase is primarily
driven by stock-based incentive compensation and non-routine stockholder action expense.
Provision for Income Taxes
The provision for income taxes was $4,008 and
$3,554 during the nine months ended September 30, 2024 and 2023, respectively.
The effective income tax rate for the nine months
ended September 30, 2024 was 30.4% compared to 32.5% in the same period last year. The statutory Federal and state tax rates remained
consistent from 2024 to 2023. The Company has items that are nondeductible or are discrete adjustments to tax expense. The Company consistently
reflects non-deductible officer compensation expense, non-deductible compensation expense related to equity incentive awards and separate
state tax rates from period to period. Although similar items were reflected in 2023, the percentage effect is different due to the difference
in pre-tax income in 2024 compared to 2023.
The Company’s effective tax rate may change
from period to period based on recurring and non-recurring factors including the relative mix of pre-tax earnings (or losses), the jurisdictional
mix of earnings, enacted tax legislation, state income taxes, the impact of non-deductible items, changes in valuation allowances, settlement
of tax audits, and the expiration of the statute of limitations in relation to unrecognized tax benefits. The Company records discrete
income tax items such as enacted tax rate changes and completed tax audits in the period in which they occur.
Income taxes are discussed in Note 10 in the Notes
to the Consolidated Financial Statements.
Liquidity and Capital Resources
Management assesses the Company's liquidity
in terms of its ability to generate cash to fund its operating, investing, and financing activities. The Company remains in a strong financial
position, and while it has been impacted by the macroeconomic challenges with commodity inflation and other input cost increases, the
Company believes that its cash flow from operations, revolving credit, and cash and cash equivalents will continue to provide sufficient
liquidity for its working capital needs, capital resource requirements, and growth initiatives and to ensure the continuation of the Company
as a going concern.
25
If additional borrowings are needed,
$5,000 was available under the Revolving Credit Facility as of September 30, 2024 (see Note 7, Debt). We are in compliance with the terms
of the Credit Agreement and expect to meet foreseeable financial requirements. The success of our business and financing strategies will
continue to provide us with the financial flexibility to take advantage of various opportunities as they arise. To date, we have been
successful in generating cash and obtaining financing as needed. However, if a serious economic or credit market crisis ensues, it could
have a negative effect on our liquidity, results of operations and financial condition.
The Company’s most significant
ongoing short-term cash requirements relate primarily to funding operations (including expenditures for raw materials, labor, manufacturing
and distribution, trade and promotions, advertising and marketing, and income tax liabilities) as well as expenditures for property, plant
and equipment.
Long-term cash requirements primarily
relate to funding deferred income taxes (see Note 10, Income Taxes, in our Annual Report on Form 10-K).
Cash Flow
The following table is derived from our Consolidated
Statement of Cash Flows:
Nine months Ended
September 30,
Net Cash Flows Provided By (Used In):
2024
2023
Operating activities
$ 15,541
$ 12.144
Investing activities
$ (5,431 )
$ (3,206 )
Financing activities
$ (2,750 )
$ (750 )
Operating Activities
Net cash provided by operating activities was
$15,541 during the nine-month period ended September 30, 2024 compared to $12,144 in the same period in 2023. The increase is primarily
due to higher cash earnings driven by increased product volumes.
Investing Activities
Net cash used in investing activities was $5,431
during the nine-month period ended September 30, 2024 compared to $3,206 in the same period in 2023. The increase in cash used reflects
our planned capital spending increase during 2024 compared to 2023. Our capital spending is focused in three core areas: growth, cost
reduction, and facility improvements. Growth capital spending supports capacity expansion and new product innovation and enhancements.
Cost reduction and facility improvements support manufacturing efficiency, safety, and productivity. We continue to make capital expenditures
primarily to modernize manufacturing facilities and support productivity initiatives.
Financing Activities
Net cash used in financing activities was $2,750
and $750 during the nine-month period ended September 30, 2024 and 2023, respectively. The cash used represents the quarterly principal
payments under the term loan. The Company paid the outstanding term loan balance of $2,250 in full during the second quarter of 2024.
26
Debt Obligations
The Company is party to an Amended and Restated
Loan and Security Agreement (as amended and modified from time to time, the “Credit Agreement”) with its existing lender and
certain of its subsidiaries. The Credit Agreement provides for, among other things, a $5 million term loan to be repaid in quarterly installments
of principal and interest over a term of five years, a revolving line of credit up to a maximum of $5 million (the “Revolving Credit
Facility”) and an incremental facility not to exceed $5 million. The termination date of the term loan is August 18, 2026, unless
earlier terminated. The term loan was terminated during the second quarter of 2024 upon payment of the outstanding loan balance in full.
The termination date of the revolving credit facility is June 30, 2025, unless earlier terminated.
As of September 30, 2024, the Company had $0 outstanding
under the Revolving Credit Facility and note payable. The Company had $5,000 available for future borrowings under the Revolving Credit
Facility as of September 30, 2024.
All outstanding amounts under the loans bear interest
at the Secured Overnight Financing Rate (“SOFR”), plus 2.07%. Interest is payable monthly in arrears. Lifeway is also required
to pay a quarterly unused line fee of 0.20% on the Revolving Credit Facility, and in conjunction with the issuance of any letters of credit,
a letter of credit fee of 0.20%.
The Company is in compliance with all applicable
financial debt covenants as of September 30, 2024. See Note 7 to our Consolidated Financial Statements for additional information regarding
our indebtedness and related agreements.
Recent Accounting Pronouncements
Information regarding recent accounting pronouncements
is provided in Note 2 – Summary of Significant Accounting Policies.
Critical Accounting Policies and Estimates
A description of the Company's critical accounting
policies and estimates is contained in its Annual Report on Form 10-K for the year ended December 31, 2023. There were no material changes
to the Company’s critical accounting policies and estimates in the nine months ended September 30, 2024.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
Not applicable.
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.